Glembatumumab Vedotin May Be Effective in Some with gpNMB-Expressing Breast Cancer

Share this content:
Glembatumumab vedotin may be effective in some patients with gpNMB-expressing breast cancer.
Glembatumumab vedotin may be effective in some patients with gpNMB-expressing breast cancer.

Glembatumumab vedotin is well tolerated in heavily pretreated patients with breast cancer and may be effective in some patients with glycoprotein NMB (gpNMB)-expressing breast cancer, a new study published online early in the Journal of Clinical Oncology has shown.

For the phase II study, researchers enrolled 124 patients with refractory breast cancer that overexpressed gpNMB, a negative prognostic marker.

Participants were randomly assigned 1:1 to receive glembatumumab vedotin or investigator's choice chemotherapy.

Results showed that the overall response rate was 6% for the glembatumumab vedotin group versus 7% for the chemotherapy group.

RELATED: Bevacizumab Window Period May Be Effective for Brain Metastases of Breast Cancer

Unplanned analysis showed an objective response rate of 18% in the glembatumumab vedotin group versus 0% in the chemotherapy group in patients with triple-negative breast cancer (TNBC).

In those with gpNMB-overexpressing TNBC, the objective response rates were 40% and 0% in the glembatumumab and chemotherapy groups, respectively.

Preliminary findings were presented at the 36th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas in 2013.

Reference

  1. Yardley DA, Weaver R, Melisko ME, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced-glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.56.2959.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters